BRAF and non-small cell lung carcinoma: A total of 34 patients with advanced stage NSCLC BRAF mutant (83% V600E) were treated with vemurafenib (n = 29), 5 of them were treated as first-line systemic treatment, dabrafenib (n = 9) or sorafenib (n = 1).